Amgen Announces $900 Million Manufacturing Expansion in Ohio, Creating 350 New Jobs
Key Insights
Biotechnology giant Amgen is investing $900 million to expand its New Albany (search), Ohio facility, bringing its total investment in the region to over $1.4 billion and creating 350 new jobs.
The expansion reinforces Amgen's commitment to U.S.-based manufacturing capabilities, leveraging Ohio's supportive business climate, skilled workforce, and strategic location.
Construction has already begun on the state-of-the-art biomanufacturing facility, which will incorporate advanced automation and artificial intelligence technologies, with completion expected by 2027.
Biotechnology leader Amgen announced a significant $900 million expansion of its manufacturing facility in New Albany (search), Ohio on Friday. The investment will create 350 new jobs, bringing the total employment at the site to 750 and Amgen's total investment in Central Ohio to more than $1.4 billion.
Construction on the expansion has already begun, with completion expected in 2027. The project represents a major commitment to advanced biomanufacturing in the United States and strengthens Ohio's growing reputation as a biotech hub.
"Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today's investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines," said Robert A. Bradway, chairman and chief executive officer at Amgen.
Strategic Investment in Advanced Manufacturing
The New Albany (search) facility will incorporate cutting-edge technologies, including extensive automation and artificial intelligence systems. Sandra Rodriguez-Toledo, Amgen Vice President of Site Operations, emphasized the innovative approach: "When we started, we start with an idea. And the idea was to have the most advanced assembly operation, in terms of automation and having artificial intelligence."
This expansion enhances Amgen's global biomanufacturing network and follows the company's recent announcement of a $1 billion investment to build a second manufacturing plant in Holly Springs, North Carolina. These investments position Amgen to develop what the company describes as "the most cutting-edge biologics manufacturing capabilities in the world."
Economic Impact and State Support
Ohio officials have welcomed the expansion as a significant economic development win for the state. Governor Mike DeWine noted, "Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth. We are happy to see Amgen deepen its commitment to our state and look forward to the innovation and economic impact it will drive."
The announcement event featured several prominent figures, including Lieutenant Governor Jim Tressel and Congressman Troy Balderson, underscoring the project's importance to the region.
Amgen's Growing U.S. Manufacturing Footprint
Amgen first established its presence in Ohio in June 2021 when it announced plans for the initial biomanufacturing facility in New Albany (search). That investment created 400 jobs and marked the company's expansion into the Columbus Region.
Since the passage of the Tax Cuts and Jobs Act of 2017, Amgen has invested almost $5 billion in direct capital expenditures in the United States. According to the company, these investments have generated approximately $12 billion in additional downstream output to the U.S. economy.
Therapeutic Focus and Company Profile
Founded more than 40 years ago, Amgen has been instrumental in establishing the biotechnology industry. The company develops medicines for serious conditions including cancer (search), heart disease (search), osteoporosis (search), inflammatory diseases (search), and rare diseases (search).
Amgen has received notable recognition in 2024, being named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes. The company is part of both the Dow Jones Industrial Average and the Nasdaq-100 Index.
The expansion in Ohio will support Amgen's continued development and manufacturing of biologic medicines, reinforcing the company's position as a leader in the biotechnology sector while bringing significant economic benefits to Central Ohio.